Search

Introduction: Helicobacter pylori is the most common bacterial infection in humans. H. pylori is now known to be responsible for chronic gastritis, peptic ulcer, B-cell gastric lymphoma, and gastric adenocarcinoma. Laparoscopic sleeve gastrectomy (LSG) is increasingly preferred among surgical treatment methods in obese patients. Aim: To discuss the detection and treatment of H. pylori in patients undergoing LSG surgery. Material and methods: Patients who underwent biopsy with upper gastrointestinal endoscopy in the preoperative and postoperative period of LSG between 2014 and 2019 were included in the study, resulting in a sample of 162 patients who underwent preoperative and postoperative endoscopy. Endoscopic biopsies of these patients were collected in accordance with the preoperative Sydney protocol. The patients did not receive H. pylori-related eradication treatment. Endoscopy was performed to investigate dyspeptic complaints in the postoperative period. The biopsy results obtained in the endoscopy in the postoperative period were compared to those obtained in the preoperative period. Results: Of the 162 patients in our study, 39 were male and 123 were female. All patients were assigned to one of two groups in the preoperative period: H. pylori (+) and H. pylori (-). H. pylori was found to be positive in 99 patients in the preoperative period. H. pylori was negative in 62 patients in the biopsy results of these patients after the LSG. H. pylori was found to be negative in 63 patients in the preoperative period, and 51 patients were H. pylori-negative in the biopsy results of these patients following LSG. These changes were found to be statistically significant when the preoperative and postoperative pathology results were evaluated (p < 0.01). Conclusions: This study showed that LSG reduced the presence of H. pylori. [ABSTRACT FROM AUTHOR]

The COVID-19 pandemic caused by SARS-CoV-2 commenced in Wuhan China in 2019 and soon spread worldwide. SARS-CoV-2 enters the cell by binding to the ACE II receptor and begins viral replication. The effects and clinical findings of SARS-CoV-2 on the liver, kidney, heart, gastrointestinal (GI) system and especially lungs have been widely discussed. However, the effects on the pancreas—another organ that also expresses ACE II—have not been studied. This work prospectively evaluated data from 316 patients who were admitted with a diagnosis of COVID-19 pneumonia. The patients were categorized into three according to the severity of pneumonia (mild, severe, critical). Demographic data, rate of pancreatitis, biochemical parameters, and radiological images from each group were analyzed. The patients were divided into two groups and outcomes were compared: COVID-19 patients with acute pancreatitis (Group P) and without acute pancreatitis (Group C). The median age was 54 (18–87), and the median age for patients with acute pancreatitis was 55 (26–84). As an expected finding, we found a positive correlation between advanced age and mortality (p = 0.0003). 12.6% of the patients had acute pancreatitis. While pancreatitis was not seen in patients on mild status, the rate of pancreatitis was 32.5% in critical patients. Hospitalization and mortality rates were higher in patients with COVID-19 accompanied by acute pancreatitis (p = 0.0038 and p < 0.0001, respectively). C-Reactive Protein (CRP) and ferritin were significantly higher in those who had pancreatitis (p < 0.0001). D-Dimer and procalcitonin levels had only a small difference (p = 0.1127 and p = 0.3403, respectively) Acute pancreatitis alone is a clinical condition that can lead to mortality and may be one of the reasons for the exaggerated immune response developing in the progression of COVID-19. Our results point out that the presence of pancreatic damage triggered by SARS-CoV-2 can deteriorate the clinical condition of patients and the mortality rate may increase in these patients. [ABSTRACT FROM AUTHOR]

Objective: Tumor markers have shown little benefit as a method for screening. However, they can be used clinically for the monitoring of tumor recurrence and used as prognostic factors because higher levels have been observed in advanced disease. This study aimed to investigate the relationship between the preoperative tumor marker levels and different clinical aspects of gastric cancer. Methods: One hundred and six consecutive patients with confirmed diagnosis of gastric cancer and 106 subjects (age and sex matched) with no malignancy as control group were included prospectively in this study in 3 years. The relationships between tumor markers CEA, CA 19-9 and stage of disease, tumor differentiation, presence of ringlet cell type, presence of peritoneal carcinomatozis were investigated. Results: The serum CEA and CA 125 levels were found to be significantly elevated in gastric cancer patients than in controls. The serum level of CEA had showed a significant elevation with the presence of distant metastasis. The CA 19-9 and CA 125 levels had showed significant elevations with the presence of peritoneal carcinomatozis. Conclusions: This study showed that there is a limited clinical benefit of preoperative tumor marker measurements in gastric cancer such as estimation of peritoneal dissemination. [ABSTRACT FROM AUTHOR]

Introduction: A stoma formation is a frequently performed procedure in patients undergoing colorectal surgery. Although stoma formation is a simple process, it should be performed with caution. The aim of this study was to attract physicians' attention to this rare disease and also to identify the surgical and medical treatment options for peristomal necrotizing fasciitis as a rare complication., Materials and Methods: Risk factors including age, sex, additional diseases, previous surgical procedures, source of infection, physical findings, and vital signs of 14 patients with peristomal necrotizing fasciitis over a period of 10 years from 2005 to 2015 were retrospectively evaluated., Results: Of the 14 patients, 9 were men and 5 were women. The average age was 63.28 years (range, 45-85 years). Risk factors were also observed: diabetes mellitus, 4 (28.57%); obesity, 3 (21.42%); alcoholism, 1 (7.14%); and malignancy, 10 (71.42%). Prophylactic antibiotic treatment was given to all patients, and they all underwent debridement and stoma replacement., Conclusion: Peristomal necrotizing fasciitis is an urgent and mortal disease. Risk factors, physical findings, and infection sources should be determined, and treatment modalities should be applied immediately. Medical treatment and surgical options should be performed, and vacuum devices should also be considered when treating this complication.